Welichem Biotech Inc.

Corporate Profile CEO's Message Management Team Board of Directors Scientific Advisor Board Intellectual Property Company Location Legal Disclaimers

Psoriasis Cancer Inflammatory Bowel Disease (IBD) Symbiochem™ Discovery Platform Technology Pipelines Glossary

Fact Sheet Sedar Filing Investor Overview Financial Statements Annual Reports Stock Information Presentations FAQs

News Release Contact Us

Current Opportunities How to Apply Company Location Contact Us

Contact by Email Company Location

公司简介新闻发布时讯月刊

Symbol: WBI.V Last price: 0.06 Date: 5/16/2008 Time: 2:59pm Change: 0.00 Open: 0.10 High: 0.10 Low: 0.06 Volume: 4000
Stock Quotes From Yahoo!

News Release

Apr. 28, 2008
Welichem Filed Quarterly Report for Period Ended February 29, 2008 More...
Apr. 08, 2008
Dr. Hugh Wynne-Edwards Resigns as a Director and Chairman of the Board More...
Mar. 13, 2008
Welichem Receives Additional Contribution from NRC-IRAP to Continue Research on its Anticancer Compound, WBI-2100 More...
Feb. 25, 2008
Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema More...
Feb. 02, 2008
Welichem is Participating in BioPartnering North America Conference in February, 2008 More...
Jan. 25, 2008
Welichem Announced Change of Board Members More...
Jan. 25, 2008
Welichem Filed Quarterly Report for Period Ended November 30, 2007 More...
Nov. 30, 2007
Welichem Established Loan Facility with Major Shareholder More...
Sept. 27, 2007
Welichem Files its Annual Audited Financials for Year Ended May 31, 2007, and Announces its AGM/SGM Date More...
Sept. 07, 2007
Welichem Biotech Successfully Moves to Higher Dose for Phase I Clinical Trials More...
Aug. 07, 2007
Phase I Clinical Trial Underway for Welichem Biotech More...
July. 16, 2007
Welichem Appoints Business Development Manager More...
July. 10, 2007
Welichem Gets Approval for Phase I Clinical Trials More...
Jun. 11, 2007
Welichem Awarded Contribution from NRC-IRAP for Research on Novel Anticancer Compound More...
Jun. 07, 2007
Welichem Announces Closing Of Non-Brokered Private Placement More...
Apr. 26, 2007
Welichem Filed Quarterly Report for Period Ended February 28, 2007 More...
Apr. 13, 2007
Welichem Biotech to Report to Major Anti-Cancer Conference More...
Mar. 28, 2007
Welichem Announces Arrangement of Non-Brokered Private Placement More...
Feb. 12, 2007
Welichem Participated in BioPartnering North America Conference 2007 More...
Feb. 01, 2007
Welichem Announces Grant of Incentive Stock Options More...
Jan. 30, 2007
Welichem Filed Quarterly Report for Period Ended November 30, 2006 More...
Jan. 29, 2007
Welichem Biotech Inc. Appoints Investor Relations Officer More...
Jan. 22, 2007
Welichem’s Anti-cancer Drug Candidate Stimulates the Immune System More...
Dec 14, 2006
Welichem Biotech Inc. Reports on its Phase I Clinical Trial Schedule More...
Oct 23, 2006
Welichem Biotech Inc. Announces Investor Relations Appointment More...
Oct 19, 2006
Welichem Filed Quarterly Report for Period Ended August 31, 2006 More...
Oct 17, 2006
Welichem Holds its Annual General Meeting More...
Oct 17, 2006
Welichem Completed Major Pre-clinical Tests for Psoriasis Drug Candidate More...
Oct 04, 2006
Welichem Filed Annual Audited Financials for Year Ended May 31, 2006 and Announced AGM/SGM Date More...
Sept 26, 2006
Welichem Awarded Contribution from NRC-IRAP for Research on Novel Anticancer Compound More...
Sept 01, 2006
Welichem announces grant of incentive stock options More...
July 25, 2006
Welichem Strengthens its Financial and Development Links More...
July 12, 2006
Welichem announces closing of non-brokered private placement More...
July 6, 2006
Welichem Appoints Chief of Biology Department More...
May 12, 2006
Welichem announces grant of incentive stock options More...
April 28, 2006
Welichem Filed Quarterly Report for Period Ended February 28, 2006 More...
April 27, 2006
Welichem Announces Creation of New Controlling Shareholder More...
April 26, 2006
Welichem announces reduction of share purchase warrant price More...
April 4, 2006
Welichem annouces arrangement of non-brokered private placement More...
February 1, 2006
Welichem Biotech Inc. appoints Mr. York Yingping Guo as Chief Executive Officer More...
December 19, 2005
Welichem Anounces Management and Board Changes More...
November 23, 2005
Welichem announces resignation of Jianxiong Li as vice president More...
November 10, 2005
Welichem announces new initiatives with its Chinese strategic partners More...
October 17, 2005
Internationally Recognized Cancer Researcher Joins Welichem's Scientific/Clinical Advisory Boards More...
October 05, 2005
Welichem Biotech Inc. appoints Mr. Dan London as Chief Operating Officer More...
September 23, 2005
Welichem Reports Positive Results with its lead Cancer Agent More.
September 22, 2005
Welichem Biotech Inc. Successfully Completes First Annual and Special General Meeting More.
September 19, 2005
Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases More.
August 18, 2005
Welichem Biotech Inc. announces changes to Board of Directors More.
July 21, 2005
Welichem Biotech Inc. Grants Stock Options More.
July 7, 2005
Welichem Biotech Inc. announces changes to Board of Directors More.
June 7, 2005
Welichem Biotech Inc. completes $1.95 million private placement More.
May 24, 2005
Welichem Commences trading on TSX-V effective May 25, 2005 More.
November 1, 2004
Welichem Amalgamation with Belltech Ventures Ltd. to Form Welichem Biotech Inc More.